Real-world evidence to support HTA/payer decisions about highly innovative technologies

The Belgian healthcare payer INAMI/RIZIV has commissioned work to explore the potential of real-world evidence to close evidentiary gaps for HTA/payer decisions. Following six months of work by a multi-stakeholder group, version 1.0 of the paper Real-world evidence to support HTA/payer decisions on highly innovative technologies - Actions for stakeholders is issued for consultation from 11 October 2019 to 6 January 2020.

The introductory elements of the paper will be developed into a formal publication, but comment is requested by all international stakeholder groups on the proposed actions for stakeholders in sections 4 and 5.

A final paper will be developed after this consultation and submitted to a journal for publication. Alongside this, work will be undertaken to initiate the key action of creating a multi-stakeholder collaborative learning network to explore use of RWE to support decision-making for highly innovative technologies. By providing comment on the current version of the paper, you are not signing up to this initiative but helping us to shape it.

If you would like more information about the collaborative, learning network proposed in this paper, please contact Laura Bachelor at laura.batchelor@fipra.com.

Thank you for your input.

Karen Facey  karen.facey@ed.ac.uk
Senior Research Fellow, University of Edinburgh
Funded through the EC H2020 Impact HTA project

Question Title

* 1. Contact details (mandatory)

Question Title

* 2. Is your response:

Question Title

* 3. Which stakeholder group(s) best describe your organisation (you) - tick all that apply

T